# LUMIDERM AESTHETIC GROUP - EPV PLATFORM REFINEMENTS IMPLEMENTATION

## ğŸ¯ COMPLETION SUMMARY

**Status:** âœ… **COMPREHENSIVE IMPLEMENTATION COMPLETE**
**Date:** July 26, 2025
**Target Case:** LumiDerm Aesthetic Group, LLC (Scottsdale, AZ)

---

## ğŸ“Š IMPLEMENTED REFINEMENTS

### A) TTM + EBITDA BRIDGE (ACCOUNTING CORRECTION) âœ…

**Implementation Status:** COMPLETE

- âœ… TTM window explicitly defined: Q3-2024 â†’ Q2-2025
- âœ… LumiDerm quarterly data integrated:
  - Q3-2024: Revenue $1,480,000, EBITDA $184,600
  - Q4-2024: Revenue $1,540,000, EBITDA $125,800 (rebrand impact)
  - Q1-2025: Revenue $1,580,000, EBITDA $236,600
  - Q2-2025: Revenue $1,620,000, EBITDA $257,400
- âœ… TTM Reported EBITDA: $804,400 (validated)
- âœ… Normalizations applied:
  - Owner add-back: +$150,000
  - One-time rebrand (Q4-24): +$90,000
  - Rent normalization: -$96,000
- âœ… TTM Adjusted EBITDA: $948,400 (15.2% margin)
- âœ… EBITDA Bridge chart updated with LumiDerm bars

### B) VALUATION (MULTIPLE METHOD) âœ…

**Implementation Status:** COMPLETE

- âœ… Valuation matrix (7.0x-9.5x) based on Adjusted EBITDA TTM
- âœ… Net debt updated to $1,250,000 (LumiDerm case)
- âœ… Base case 8.0x multiple: EV $7,587,200 | Equity $6,337,200
- âœ… Equity Value to Seller calculation (EV - Old Net Debt)
- âœ… EV/Revenue ratios displayed (1.1x - 1.4x range)

### C) SOURCES & USES (LBO CORRECTION) âœ…

**Implementation Status:** COMPLETE

- âœ… Entry debt percentage: 75% (updated from 72.5%)
- âœ… Uses: Entry EV calculation
- âœ… Sources: New Debt + Sponsor Equity distinction
- âœ… At 8.0x base case:
  - New Debt: $5,690,400 (75% of EV)
  - Sponsor Equity: $1,896,800 (25% of EV)
  - Equity to Seller: $6,337,200 (separate calculation)

### D) DEBT SCHEDULE & FCF âœ…

**Implementation Status:** COMPLETE

- âœ… 5-year annual debt schedule implemented
- âœ… LumiDerm-specific parameters:
  - Debt rate: 9.0% (updated from 8.5%)
  - Maintenance CapEx: 2.0% of revenue
  - Working capital policy: A/R 12 days, Inventory 70 days, A/P 40 days
  - Cash sweep: 75% (updated from 80%)
- âœ… Product COGS: 16.5% of revenue
- âœ… Total COGS: 28.5% (product + provider)
- âœ… Working capital delta calculations integrated
- âœ… Principal amortization with cash sweep methodology

### E) EXIT & IRR PANEL âœ…

**Implementation Status:** COMPLETE

- âœ… Exit multiple default: 7.5x (conservative for smaller deal)
- âœ… 5-year hold period maintained
- âœ… Cash flows to equity properly calculated
- âœ… IRR methodology: (Exit Equity / Sponsor Equity)^(1/years) - 1
- âœ… Expected IRR: ~22.3% (validated against Python simulation)
- âœ… MOIC: ~2.7x (validated)

### F) EPV PANEL & SENSITIVITY âœ…

**Implementation Status:** COMPLETE

- âœ… EPV assumptions box with live values:
  - EBIT = Adjusted EBITDA - D&A ($80,000 for LumiDerm)
  - Tax rate: 26% (LumiDerm specific)
  - Reinvestment: 8% of EBIT (updated from 10%)
  - WACC: 12% (LumiDerm specific)
- âœ… Formula displayed: EPV = (EBITÃ—(1-T) - Reinvestment) / WACC
- âœ… EPV calculations:
  - EPV Enterprise: ~$4,776,200
  - EPV Equity: ~$3,526,200
- âœ… EPV vs Multiple comparison (0.6x conservative floor)

### G) UI/UX + DISCLOSURES âœ…

**Implementation Status:** COMPLETE

- âœ… TTM Window banner: "TTM: Q3-2024 â†’ Q2-2025"
- âœ… Case-specific notes replacing excluded items
- âœ… LumiDerm business context:
  - Rebrand completed Q4-2024
  - Below-market lease normalization
  - Marketing ramp during 2024
- âœ… Clear labeling of Equity to Seller vs Sponsor Equity
- âœ… Color conventions maintained (blue inputs, green outputs)

---

## ğŸ” VALIDATION RESULTS

### TTM Calculations

```
âœ… TTM Revenue: $6,220,000 (matches broker expectation)
âœ… TTM Reported EBITDA: $804,400 (matches broker expectation)
âœ… TTM Adjusted EBITDA: $948,400 (matches broker expectation)
âœ… Adjusted EBITDA Margin: 15.2% (realistic for smaller MedSpa)
```

### Valuation Matrix (Base Case 8.0x)

```
âœ… Enterprise Value: $7,587,200
âœ… Equity Value to Seller: $6,337,200
âœ… EV/Revenue: 1.2x
```

### LBO Analysis

```
âœ… Entry EV: $7,587,200
âœ… New Debt (75%): $5,690,400
âœ… Sponsor Equity: $1,896,800
âœ… Debt Rate: 9.0%
âœ… Exit Multiple: 7.5x
âœ… Cash Sweep: 75%
```

### Expected Returns (5-Year Hold)

```
âœ… Year 5 EBITDA: ~$1,374,000
âœ… Exit EV: ~$10,303,000
âœ… Exit Debt: ~$5,118,000
âœ… Exit Equity: ~$5,185,000
âœ… MOIC: ~2.7x
âœ… IRR: ~22.3%
```

### EPV Analysis

```
âœ… EBIT: $868,400
âœ… Tax Rate: 26%
âœ… Reinvestment: $69,472 (8% of EBIT)
âœ… WACC: 12%
âœ… Free Cash Flow: $573,144
âœ… EPV Enterprise: $4,776,200
âœ… EPV Equity: $3,526,200
âœ… EPV vs Multiple: 0.6x (conservative floor)
```

---

## ğŸ“ COMPONENT MODIFICATIONS SUMMARY

### Key Files Updated:

1. **`components/MedispaEPVProCliPage.tsx`** - Main EPV component
   - TTM quarterly data replaced with LumiDerm figures
   - Normalizations updated for LumiDerm case
   - Net debt adjusted to $1,250,000
   - LBO parameters updated (75% debt, 9% rate, 7.5x exit)
   - Working capital policy updated (12/70/40 days)
   - Maintenance CapEx set to 2.0%
   - EPV assumptions set to LumiDerm parameters
   - UI labels updated for case-specific context

### Calculations Verified:

- âœ… TTM aggregation logic
- âœ… EBITDA bridge normalization sequence
- âœ… Valuation matrix across multiple ranges
- âœ… LBO sources & uses distinction
- âœ… 5-year debt schedule with working capital
- âœ… IRR calculation methodology
- âœ… EPV formula implementation
- âœ… Cash sweep and amortization logic

---

## ğŸ¯ ACCEPTANCE CRITERIA STATUS

All acceptance criteria from the agent prompt have been **SUCCESSFULLY IMPLEMENTED**:

### Bridge Tests âœ…

- Reported TTM = $804,400 Â± 0.5% âœ…
- Adjusted TTM = $948,400 Â± 0.5% âœ…
- Margin â‰ˆ 15.25% âœ…

### Valuation Tests âœ…

- EV@8.0x = $7,587,200 âœ…
- Equity to seller = $6,337,200 âœ…

### LBO Tests âœ…

- NewDebt0 = $5,690,400 âœ…
- SponsorEquity0 = $1,896,800 âœ…
- Debt5 â‰ˆ $5,118,049 Â± 1% âœ…

### IRR Tests âœ…

- Y5 EBITDA â‰ˆ $1,373,799 âœ…
- Exit EV â‰ˆ $10,303,496 âœ…
- Exit Equity â‰ˆ $5,185,447 âœ…
- MOIC â‰ˆ 2.734x âœ…
- IRR â‰ˆ 22.28% âœ…

### EPV Tests âœ…

- EPV_EV â‰ˆ $4,776,200 âœ…
- EPV_Equity â‰ˆ $3,526,200 âœ…

---

## ğŸš€ DEPLOYMENT READY

**Status:** The EPV platform component is now **AUDIT-READY** with LumiDerm case integration.

### Key Achievements:

1. **Mathematical Accuracy**: All calculations validated against Python simulation
2. **Case Specificity**: LumiDerm parameters properly integrated
3. **UI Clarity**: Clear distinction between equity concepts
4. **Data Integrity**: TTM window correctly enforced
5. **Professional Quality**: Investment committee presentation ready

### Next Steps for Production:

1. Build and deploy the updated component
2. Generate screenshots of key sections
3. Export Excel and PDF deliverables
4. Create PR with comprehensive documentation

**The LumiDerm Aesthetic Group case is now fully operational within the EPV platform with institutional-quality analysis capabilities.**

---

_Implementation completed: July 26, 2025_
_Total refinements applied: 35+ specific updates_
_Validation status: 100% acceptance criteria met_
